CO2018012431A2 - Comprimidos de disgregación oral - Google Patents

Comprimidos de disgregación oral

Info

Publication number
CO2018012431A2
CO2018012431A2 CONC2018/0012431A CO2018012431A CO2018012431A2 CO 2018012431 A2 CO2018012431 A2 CO 2018012431A2 CO 2018012431 A CO2018012431 A CO 2018012431A CO 2018012431 A2 CO2018012431 A2 CO 2018012431A2
Authority
CO
Colombia
Prior art keywords
rapid disintegration
oral disintegration
oral
disintegration tablets
propylthio
Prior art date
Application number
CONC2018/0012431A
Other languages
English (en)
Spanish (es)
Inventor
Husban Farhan Abdel Karim Mohammad Al
Lars Håkan Christer Glad
Jenny Malin Christina Hallstein
Andrea Jane Moir
Michael Peter Thompson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58640851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018012431(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2018012431A2 publication Critical patent/CO2018012431A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035Blister-type containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/325Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
    • B65D75/327Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CONC2018/0012431A 2016-04-21 2018-11-19 Comprimidos de disgregación oral CO2018012431A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325584P 2016-04-21 2016-04-21
PCT/EP2017/059443 WO2017182589A1 (en) 2016-04-21 2017-04-20 Orally disintegrating tablets

Publications (1)

Publication Number Publication Date
CO2018012431A2 true CO2018012431A2 (es) 2018-11-30

Family

ID=58640851

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0012431A CO2018012431A2 (es) 2016-04-21 2018-11-19 Comprimidos de disgregación oral

Country Status (26)

Country Link
US (1) US10729655B2 (enExample)
EP (2) EP4417537A3 (enExample)
JP (2) JP6960941B2 (enExample)
KR (2) KR102392347B1 (enExample)
CN (3) CN107595789B (enExample)
AU (2) AU2017253367B2 (enExample)
BR (1) BR112018071440A2 (enExample)
CO (1) CO2018012431A2 (enExample)
DK (1) DK3445338T3 (enExample)
EA (1) EA201892150A1 (enExample)
ES (1) ES3014055T3 (enExample)
FI (1) FI3445338T3 (enExample)
HR (1) HRP20250204T1 (enExample)
HU (1) HUE070095T2 (enExample)
IL (1) IL262312B (enExample)
LT (1) LT3445338T (enExample)
MA (1) MA44720B1 (enExample)
PE (1) PE20190372A1 (enExample)
PH (1) PH12018502226A1 (enExample)
PL (1) PL3445338T3 (enExample)
PT (1) PT3445338T (enExample)
RS (1) RS66536B1 (enExample)
SG (2) SG10202107682QA (enExample)
SI (1) SI3445338T1 (enExample)
SM (1) SMT202500081T1 (enExample)
WO (1) WO2017182589A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450067A (zh) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 一种替格瑞洛分散片及其制备方法
CN109700773B (zh) * 2019-03-01 2021-03-16 石药集团中奇制药技术(石家庄)有限公司 一种替格瑞洛制剂组合物及其制备方法
JP7657041B2 (ja) 2020-08-19 2025-04-04 アストラゼネカ・アクチエボラーグ 併用療法
CN114712317A (zh) * 2021-01-04 2022-07-08 弘和制药有限公司 一种替格瑞洛药物组合物及其制备方法和其应用
US20220387328A1 (en) * 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy
WO2023057879A1 (en) * 2021-10-04 2023-04-13 Neurim Pharmaceuticals (1991) Ltd. Methods and products for treating subjects with autism spectrum disorders
CN120129530A (zh) 2022-10-28 2025-06-10 阿斯利康(瑞典)有限公司 以40mg至240mg的剂量用于在治疗缺血事件中使用的重组腺苷三磷酸双磷酸酶蛋白
CN116370423B (zh) * 2023-02-28 2024-11-12 天津力生制药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB516834A (en) * 1937-12-23 1940-01-12 Charles Alexandre Nicolle Improvements in or relating to packaging
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
ES2268020T3 (es) * 2001-05-10 2007-03-16 Astellas Pharma Inc. Comprimidos de disgregacion rapida de la cavidad oral y proceso para producir los mismos.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CN2717851Y (zh) 2004-05-14 2005-08-17 重庆康刻尔制药有限公司 一种药品包装板
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
CN102058889A (zh) * 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
FR2968992B1 (fr) 2010-12-16 2013-02-08 Sanofi Aventis Comprime pharmaceutique orodispersible a base de zolpidem
US20130160408A1 (en) 2011-12-22 2013-06-27 Gregor N. Neff Blister Pack and Method
WO2013115171A1 (ja) 2012-02-03 2013-08-08 旭化成ケミカルズ株式会社 苦味マスク顆粒含有口腔内崩壊錠
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103964066B (zh) * 2013-02-06 2017-09-19 李和伟 一种冻干赋型制剂的包装装置
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型,以及制备方法和药物应用
EA201691582A1 (ru) * 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты

Also Published As

Publication number Publication date
EP4417537A2 (en) 2024-08-21
HRP20250204T1 (hr) 2025-04-11
JP2022009050A (ja) 2022-01-14
CN107595789A (zh) 2018-01-19
PE20190372A1 (es) 2019-03-08
JP6960941B2 (ja) 2021-11-05
CN107530288B (zh) 2022-01-25
WO2017182589A9 (en) 2018-04-19
AU2020201930B2 (en) 2020-10-29
EA201892150A1 (ru) 2019-05-31
SG10202107682QA (en) 2021-08-30
KR102392347B1 (ko) 2022-05-02
PL3445338T3 (pl) 2025-03-31
CN107530288A (zh) 2018-01-02
WO2017182589A1 (en) 2017-10-26
HUE070095T2 (hu) 2025-05-28
CN107595789B (zh) 2021-01-15
AU2017253367B2 (en) 2020-04-16
RS66536B1 (sr) 2025-03-31
KR20180132147A (ko) 2018-12-11
PH12018502226A1 (en) 2019-07-29
MA44720B1 (fr) 2025-02-28
PT3445338T (pt) 2025-03-03
DK3445338T3 (da) 2025-02-10
CN107595790A (zh) 2018-01-19
US10729655B2 (en) 2020-08-04
SMT202500081T1 (it) 2025-03-12
MA44720A (fr) 2019-02-27
KR20220054907A (ko) 2022-05-03
SG11201808996SA (en) 2018-11-29
JP7254871B2 (ja) 2023-04-10
ES3014055T3 (en) 2025-04-16
FI3445338T3 (fi) 2025-01-29
KR102488486B1 (ko) 2023-01-12
AU2017253367A1 (en) 2018-11-08
JP2019516674A (ja) 2019-06-20
EP3445338A1 (en) 2019-02-27
LT3445338T (lt) 2025-02-25
US20190117577A1 (en) 2019-04-25
IL262312A (en) 2018-11-29
EP3445338B1 (en) 2024-11-27
HK1249732A1 (zh) 2018-11-09
IL262312B (en) 2022-08-01
HK1248562A1 (zh) 2018-10-19
EP4417537A3 (en) 2024-12-04
AU2020201930A1 (en) 2020-04-09
CN107595790B (zh) 2021-01-12
BR112018071440A2 (pt) 2019-02-05
SI3445338T1 (sl) 2025-03-31

Similar Documents

Publication Publication Date Title
CO2018012431A2 (es) Comprimidos de disgregación oral
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2013000933A1 (es) Compuestos derivados de furo[3,2-d]pirimidina y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una afeccion que esta mediada por la actividad de una proteina quinasa, tal como cancer, trastornos cardiovasculares, del snc e inmunes, y enfermedades relacionadas con la inmunodeficiencia adquirida.
CL2015000483A1 (es) Compuestos derivados biciclicos fusionados de sulfamoilo; composicion farmaceutica que los comprende; y producto que los contiene.
HUE043122T2 (hu) Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk
WO2018119395A8 (en) Compounds, compositions and methods of use
USD732961S1 (en) Vodka bottle
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
UY36176A (es) Formas cristalinas de (2r, 5s, 13ar)-8-hidroxi-7,9- dioxo- n-(2,4,6 - trifluorobencil)-2,3,4,5,7,9,13,13a -octahidro -2,5- metanopirido[1?,2?,4,5]pirazino[2,1-b][1,3]oxazapina- 10-carboxamida
CL2014002732A1 (es) Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras.
EA201590745A1 (ru) Твердая пероральная фармацевтическая композиция, содержащая тикагрелор
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
MX339408B (es) Composiciones farmaceuticas entericas resistentes al alcohol.
ES2636936T3 (es) Derivados de triazolo[4,5-d]pirimidina para el tratamiento de enfermedades tales como cáncer
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
ECSP17011672A (es) Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
NI201400101A (es) Inhibidores de cinasa de fosfoinositida 3 cristalina
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
UY36190A (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
WO2016066726A3 (en) Active acrylamides
EA024825B8 (ru) Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение